دورية أكاديمية
Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers.
| العنوان: | Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. |
|---|---|
| المؤلفون: | Cargill KR; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Hasken WL; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gay CM; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Byers LA; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States. |
| المصدر: | Frontiers in oncology [Front Oncol] 2021 Oct 21; Vol. 11, pp. 757323. Date of Electronic Publication: 2021 Oct 21 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Metabolic reprogramming is a hallmark of cancer initiation, progression, and relapse. From the initial observation that cancer cells preferentially ferment glucose to lactate, termed the Warburg effect, to emerging evidence indicating that metabolic heterogeneity and mitochondrial metabolism are also important for tumor growth, the complex mechanisms driving cancer metabolism remain vastly unknown. These unique shifts in metabolism must be further investigated in order to identify unique therapeutic targets for individuals afflicted by this aggressive disease. Although novel therapies have been developed to target metabolic vulnerabilities in a variety of cancer models, only limited efficacy has been achieved. In particular, lung cancer metabolism has remained relatively understudied and underutilized for the advancement of therapeutic strategies, however recent evidence suggests that lung cancers have unique metabolic preferences of their own. This review aims to provide an overview of essential metabolic mechanisms and potential therapeutic agents in order to increase evidence of targeted metabolic inhibition for the treatment of lung cancer, where novel therapeutics are desperately needed. Competing Interests: CG serves in a consulting and advisory capacity for AstraZeneca, Kisoji Biotechnology, and Bristol Myers Squibb. CG is also a part of Speaker’s Bureau for AstraZeneca and Beigene. LB serves on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA, Sierra Oncology, Merck, Bristol Myers Squibb, Genentech, and Pfizer. LB also receives research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology, Tolero Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Cargill, Hasken, Gay and Byers.) |
| References: | Nat Chem Biol. 2016 Nov;12(11):937-943. (PMID: 27618187) Mol Cell. 2019 Dec 5;76(5):838-851.e5. (PMID: 31564558) Cancer. 1983 Mar 15;51(6):1056-61. (PMID: 6295620) Nature. 2019 May;569(7757):503-508. (PMID: 31068700) Cancer Sci. 2016 Dec;107(12):1755-1766. (PMID: 27627196) Biomark Insights. 2018 Feb 06;13:1177271918755391. (PMID: 29449774) Oncotarget. 2017 Jan 3;8(1):133-144. (PMID: 27863400) Cell. 2015 Sep 10;162(6):1229-41. (PMID: 26321679) Mol Cancer Ther. 2014 Dec;13(12):2805-16. (PMID: 25281618) Oncotarget. 2017 Sep 1;8(43):73419-73432. (PMID: 29088717) Oncotarget. 2017 Sep 6;8(43):75206-75216. (PMID: 29088858) Nat Med. 2017 Nov;23(11):1362-1368. (PMID: 28967920) Cell Metab. 2018 Sep 4;28(3):369-382.e5. (PMID: 30043754) J Thorac Dis. 2010 Mar;2(1):48-51. (PMID: 22263017) Cancer Manag Res. 2019 Apr 17;11:3295-3313. (PMID: 31114366) Clin Orthop Relat Res. 2010 Nov;468(11):2833-9. (PMID: 20809165) J Egypt Natl Canc Inst. 2018 Dec;30(4):125-131. (PMID: 30337185) Front Oncol. 2017 Aug 28;7:193. (PMID: 28894699) Cancer Cell. 2021 Mar 8;39(3):346-360.e7. (PMID: 33482121) Nat Med. 2013 Nov;19(11):1469-1472. (PMID: 24162815) Eur J Pharmacol. 2014 Oct 15;741:8-16. (PMID: 25084222) Cell Biosci. 2019 Jun 26;9:52. (PMID: 31391918) Front Oncol. 2019 Nov 15;9:1215. (PMID: 31803611) Cancers (Basel). 2019 Aug 16;11(8):. (PMID: 31426364) PLoS One. 2017 Apr 20;12(4):e0175549. (PMID: 28426686) Front Oncol. 2019 Nov 01;9:1143. (PMID: 31737570) Cell Rep. 2016 Aug 2;16(5):1259-1272. (PMID: 27452466) Cancer Res. 2017 Mar 15;77(6):1245-1249. (PMID: 28246276) Cancer Cell. 2017 Feb 13;31(2):270-285. (PMID: 28089889) Br J Cancer. 2019 Jul;121(1):51-64. (PMID: 31114017) Radiother Oncol. 2009 Sep;92(3):329-33. (PMID: 19604589) J Clin Invest. 2021 Jan 4;131(1):. (PMID: 33079728) Oncotarget. 2018 Mar 30;9(24):16807-16821. (PMID: 29682186) Int J Oncol. 2010 Dec;37(6):1575-81. (PMID: 21042727) Oxid Med Cell Longev. 2016;2016:1580967. (PMID: 27547291) Thorac Cancer. 2019 Apr;10(4):839-847. (PMID: 30793508) Int J Mol Sci. 2019 Jan 09;20(2):. (PMID: 30634433) Cancer Cell Int. 2016 Feb 16;16:9. (PMID: 26884725) Cancer Cell. 2013 Feb 11;23(2):143-58. (PMID: 23352126) Cell Death Discov. 2021 Jan 18;7(1):15. (PMID: 33462221) Cancer Cell. 2018 Mar 12;33(3):355-367.e7. (PMID: 29533781) Cancer Discov. 2015 Oct;5(10):1024-39. (PMID: 26382145) Int J Mol Sci. 2019 Jan 08;20(1):. (PMID: 30626133) Front Cell Dev Biol. 2017 Apr 11;5:35. (PMID: 28443280) Trends Biochem Sci. 2016 Mar;41(3):211-218. (PMID: 26778478) Front Oncol. 2019 Aug 30;9:848. (PMID: 31544066) Adv Exp Med Biol. 2012;942:287-308. (PMID: 22399428) Clin Cancer Res. 2014 Feb 15;20(4):926-937. (PMID: 24277449) Clin Lung Cancer. 2006 Jan;7(4):268-72. (PMID: 16512981) Oncol Lett. 2018 Mar;15(3):3415-3421. (PMID: 29467866) Nat Cancer. 2020 Apr;1(4):437-451. (PMID: 35121965) Cancer Res. 1985 Jun;45(6):2924-30. (PMID: 2985258) Mol Cancer Ther. 2012 Aug;11(8):1672-82. (PMID: 22689530) J Cancer. 2020 May 18;11(15):4442-4452. (PMID: 32489463) Ann Oncol. 2000 Oct;11(10):1335-41. (PMID: 11106124) Immune Netw. 2018 Feb 22;18(1):e14. (PMID: 29503744) Nat Cancer. 2020 Apr;1:423-436. (PMID: 33521652) Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287) Lung Cancer. 2010 Sep;69(3):279-83. (PMID: 20018398) World J Surg Oncol. 2018 Mar 20;16(1):60. (PMID: 29558957) Cancer Med. 2019 Apr;8(4):1459-1466. (PMID: 30773851) Nat Commun. 2021 May 5;12(1):2540. (PMID: 33953163) Mol Metab. 2019 Feb;20:1-13. (PMID: 30553771) Genes Cancer. 2010 Dec;1(12):1170-7. (PMID: 21779440) Cancers (Basel). 2019 Mar 29;11(4):. (PMID: 30934955) J Thorac Oncol. 2012 Mar;7(3):567-73. (PMID: 22157370) J Exp Med. 2014 May 5;211(5):781-90. (PMID: 24778419) Nat Rev Cancer. 2019 May;19(5):289-297. (PMID: 30926931) Nat Rev Cancer. 2014 Aug;14(8):535-46. (PMID: 25056707) Oncogene. 2019 Apr;38(15):2778-2787. (PMID: 30542115) Genes Dev. 2018 Jul 1;32(13-14):915-928. (PMID: 29945888) J Biomed Biotechnol. 2010;2010:150960. (PMID: 20617134) Lung Cancer. 2020 Mar;141:64-71. (PMID: 31955002) Cell Cycle. 2011 Aug 15;10(16):2806-15. (PMID: 21822053) Nat Genet. 2012 Oct;44(10):1104-10. (PMID: 22941188) Cancer Chemother Pharmacol. 2013 Aug;72(2):445-52. (PMID: 23807323) Nature. 2010 Jan 21;463(7279):364-8. (PMID: 20010808) Cancer Res. 2004 Jan 1;64(1):31-4. (PMID: 14729604) Oncogene. 1992 Mar;7(3):451-7. (PMID: 1312700) Front Immunol. 2018 Feb 23;9:353. (PMID: 29527212) Nutr Metab (Lond). 2010 Jan 27;7:7. (PMID: 20181022) Mol Cancer. 2019 Jan 9;18(1):7. (PMID: 30626401) J Biol Chem. 2009 Aug 28;284(35):23225-33. (PMID: 19574224) Nature. 2017 May 18;545(7654):360-364. (PMID: 28489825) J Exp Clin Cancer Res. 2019 Nov 12;38(1):462. (PMID: 31718692) Eur J Pharmacol. 2020 Dec 5;888:173486. (PMID: 32805254) Semin Cell Dev Biol. 2020 Feb;98:54-62. (PMID: 31238096) Cell Rep. 2019 Oct 1;29(1):135-150.e9. (PMID: 31577944) Oxid Med Cell Longev. 2019 Jun 25;2019:7346492. (PMID: 31341534) Cancers (Basel). 2019 Aug 09;11(8):. (PMID: 31405035) Cancer Immunol Immunother. 2019 Mar;68(3):341-352. (PMID: 30725206) J Biol Chem. 2015 Jul 10;290(28):17495-504. (PMID: 26023239) Nat Rev Drug Discov. 2019 Sep;18(9):669-688. (PMID: 31363227) J Thorac Oncol. 2015 Aug;10(8):1133-41. (PMID: 26039012) Nature. 2015 Aug 6;524(7563):47-53. (PMID: 26168399) Nat Commun. 2018 Mar 13;9(1):1048. (PMID: 29535388) Am J Respir Crit Care Med. 2015 Feb 15;191(4):448-54. (PMID: 25522257) Cancer Res. 2019 Jul 1;79(13):3251-3267. (PMID: 31040157) Front Endocrinol (Lausanne). 2018 Aug 21;9:372. (PMID: 30186229) Cancer Cell. 2020 Jul 13;38(1):60-78.e12. (PMID: 32473656) J Geriatr Oncol. 2017 Jan;8(1):23-30. (PMID: 27264267) Clin Cancer Res. 2013 Feb 1;19(3):560-70. (PMID: 23213057) Lung Cancer. 1994 Sep;11(3-4):275-81. (PMID: 7812704) Cancer Metab. 2017 Oct 3;5:8. (PMID: 29026541) Cell Rep. 2016 Aug 9;16(6):1614-1628. (PMID: 27477280) Cell Commun Signal. 2020 Jun 23;18(1):98. (PMID: 32576270) N Engl J Med. 1948 Jun 3;238(23):787-93. (PMID: 18860765) Transl Lung Cancer Res. 2014 Feb;3(1):53-63. (PMID: 25806281) PLoS One. 2016 Oct 12;11(10):e0164244. (PMID: 27732654) Clin Cancer Res. 2019 Aug 15;25(16):5107-5121. (PMID: 31164374) J Biol Chem. 2008 Aug 15;283(33):22700-8. (PMID: 18541534) PLoS One. 2009 Jun 24;4(6):e6029. (PMID: 19551151) J Thorac Cardiovasc Surg. 2016 Jul;152(1):55-61.e1. (PMID: 27157918) Br J Cancer. 1998;78 Suppl 3:1-7. (PMID: 9717984) Oncol Lett. 2012 Dec;4(6):1151-1157. (PMID: 23226794) Cell Metab. 2014 May 6;19(5):795-809. (PMID: 24726384) Front Oncol. 2017 Dec 11;7:306. (PMID: 29376023) Cell Rep. 2017 Jan 17;18(3):601-610. (PMID: 28099841) J Cancer. 2019 Aug 27;10(20):4989-4997. (PMID: 31598171) Oncotarget. 2017 Jul 25;8(30):49275-49292. (PMID: 28525376) Nature. 2012 Sep 27;489(7417):519-25. (PMID: 22960745) Lung Cancer. 1996 Aug;15(1):115-23. (PMID: 8865129) Oncogene. 1991 Oct;6(10):1775-8. (PMID: 1656362) Elife. 2016 Jun 10;5:. (PMID: 27282387) Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93. (PMID: 25267614) Biomolecules. 2020 May 20;10(5):. (PMID: 32443774) Cancer Res. 1985 Jun;45(6):2913-23. (PMID: 2985257) EBioMedicine. 2019 Apr;42:431-442. (PMID: 30935888) Cell Death Dis. 2019 Sep 27;10(10):725. (PMID: 31562297) Cell Metab. 2017 Jul 5;26(1):94-109. (PMID: 28683298) Ann Oncol. 2001 Apr;12(4):557-61. (PMID: 11398892) J Exp Clin Cancer Res. 2017 Jan 7;36(1):7. (PMID: 28061878) Cancer Discov. 2021 Sep;11(9):2334-2353. (PMID: 33879449) Front Oncol. 2018 Nov 02;8:500. (PMID: 30456204) Transl Lung Cancer Res. 2016 Aug;5(4):450-1. (PMID: 27676363) Cell. 2017 Oct 5;171(2):358-371.e9. (PMID: 28985563) Front Cell Dev Biol. 2019 Jan 29;7:4. (PMID: 30761299) J Oncol. 2019 Feb 3;2019:5245034. (PMID: 30853982) Exp Mol Med. 2016 Dec 9;48(12):e277. (PMID: 27932791) Clin Lung Cancer. 2013 Jan;14(1):28-33. (PMID: 22537509) Cancer Chemother Pharmacol. 2014 Feb;73(2):417-27. (PMID: 24352250) Cell. 2016 Feb 11;164(4):681-94. (PMID: 26853473) Transl Lung Cancer Res. 2016 Jun;5(3):288-300. (PMID: 27413711) |
| معلومات مُعتمدة: | P30 CA016672 United States CA NCI NIH HHS; R01 CA207295 United States CA NCI NIH HHS; T32 CA009666 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: glycolysis (Warburg effect); lung cancer; metabolic inhibitors; metabolism; oxidative phosphorylation |
| تواريخ الأحداث: | Date Created: 20211108 Latest Revision: 20240404 |
| رمز التحديث: | 20240404 |
| مُعرف محوري في PubMed: | PMC8566922 |
| DOI: | 10.3389/fonc.2021.757323 |
| PMID: | 34745994 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!